BioSpace News Archive

Nura announced that it will begin providing free Narcan® kits and training directly to select patients who take opiate analgesics.

Hospital for Special Surgery (HSS), the top-ranked orthopedic hospital in the nation, announced the appointments of Harvinder S. Sandhu, MD, MBA, and Andrew A. Sama, MD, as the new co-chiefs of its spine service, effective October 2019.

DURECT Corporation announced that James E. Brown, Chief Executive Officer will be presenting at the Cantor Fitzgerald Global Health Care Conference, at the InterContinental New York Barclay Hotel on Friday, October 4, 2019 at 10:40 a.m. EDT.

Spectrum Therapeutics, the medical division of Canopy Growth Corporation is pleased to announce a donation to the Fondation de l’Hôpital du Sacré-Coeur de Montreal to support the Canadian Sleep and Circadian Network’s associated national campaign: Sleep On It which aims to raise awareness about the importance of good quality sleep on health.

Talaris Therapeutics, Inc. announced that CEO Scott Requadt will present at the annual Cell & Gene Meeting on the Mesa to be held October 2-4 in Carlsbad, California.

VBI Vaccines Inc. announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ option to purchase additional shares.

Lineage Cell Therapeutics, Inc. announced that Brandi L. Roberts, Chief Financial Officer, will be presenting at the 2019 Cantor Global Healthcare Conference on October 4th, 2019 at 1:45pm Eastern Time at the InterContinental Barclay Hotel in Grand Ballroom 1 in New York, NY.

Aldeyra Therapeutics, Inc. announced that it will host an ePoster presentation and discussion of the company’s ALLEVIATE Phase 3 clinical trial of reproxalap in patients with allergic conjunctivitis at the American Academy of Ophthalmology 2019 Annual Meeting, which takes place October 12-15, 2019 at the Moscone Center in San Francisco, California.

Black Diamond Therapeutics, Inc. announced that preclinical data defining the molecular mechanism for oncogenic activation of families of epidermal growth factor receptor allosteric mutations and showing activity of the Company’s lead product candidate BDTX-189 will be presented at the European Society for Medical Oncology Congress 2019, taking place from September 27 to October 1, 2019 in Barcelona, Spain.

ZielBio, Inc., an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes, has closed a $25.1 million Series A financing round.